View Older Stories View More Recent Stories
-
Roth Capital Starts Acuity Brands (AYI) at Neutral; Sees Bar Set High for Market Leader
-
Roth Capital Assumes LSI Industries (LYTS) at Buy; Positive on New Management, Down Lighting Opportunity
-
Roth Capital Starts Cree (CREE) at Buy; Positive on Growth Outlook for Lighting Products Unit
-
Hudson Technologies (HDSN) Sees Continued Momentum as Hot Summer Weather Lingers - Roth Capital
-
Roth Affrims Trina Solar (TSL) at 'Neutral'; Industry Supply-Demand Imbalances Mar Visibility
-
Roth Capital Reiterates $32 PT on Stemline Therapeutics (STML) as Breakthrough Therapy Granted
-
Roth Capital Doubles PT on Clean Diesel Technologies (CDTI) to $4; Sees Improving Balance Sheet Metrics
-
Roth Capital Positive on Sky Solar's (SKYS) Move to Sell Japanese Solar Project Assets; Affirms at 'Buy'
-
Notable Analyst Rating Changes 8/22: (BRX) (HRL) (VNCE) Upgraded; (RLYP) (WDAY) (TRNO) Downgraded
-
Notable Mergers and Acquisitions 8/22: (PFE)/(MDVN) (CST) (CIFC) (MOBI)
-
Sky-mobi Limited (MOBI) Enters 'Going Private' Deal at $2.20/ADS
-
Sky-mobi Limited Enters into Definitive Agreement for Going Private Transaction
-
Roth Capital Starts Platform Specialty Products (PAH) at Buy
-
Roth Sees Canadian Solar's (CSIQ) Cost Management Actions Panning Out; Affirms at 'Buy'
-
Roth Capital Sees Ballard Power's (BLDP) Deal with Toyota as 'Significant' Positive; Affirms at 'Buy'
-
Roth Capital Cuts PT on Cerulean Pharma (CERU) to $2.50 Following CRLX101 Combo Phase 2 Data
-
Roth Capital Positive on Cytokinetics (CYTK) Following 'Milestone' ALS Study Enrollment
-
Roth Says Quest Resource (QRHC) Q2 Results Inline, but SG&A Continues to Run High
-
Roth Capital Keeps Heat Biologics (HTBX) at 'Buy' at Q4 Inflection Points Near
-
Zosano Pharma (ZSAN) Prices Common Stock, Warrants Private Placement at $1.57/Unit
-
Zosano Pharma Announces Pricing of Private Placement of Common Stock and Warrants
-
Roth Capital Keeps VBL Therapeutics (VBLT) at 'Buy' Following Q2 Results; Glioblastoma Remains in Focus
-
Roth Capital Trims PT on Plug Power (PLUG) to $1.75 Following Q2 Report
-
Roth Capital Says, Amid Global Water's (GWRS) Muddle Q2, Key Catalysts Approach
-
Roth Keeps Ballard Power (BLDP) at 'Buy' Following Meetings with Management; Positive on Telecom Sale
-
Roth Capital Trims PT on Energy Focus (EFOI) to $5 Following Q2 Results
-
Roth Remains Positive on BioLineRx (BLRX) Following Q2 Report, CEO Succession
-
Roth Capital Downgrades Marchex (MCHX) to Neutral
-
Radisys to Participate at Upcoming Financial Conferences
-
Roth Capital Upgrades Clayton Williams Energy (CWEI) to Neutral
-
Fibrocell Announces Proposed Public Offering of Common Stock and Warrants
-
TG Therapeutics (TGTX) Seen Firing on All Cylinders Post-Q2 Results; Roth Affirms at 'Buy'
-
Vista Gold Corp. Completes Previously Announced US$17.3 Million Bought Deal Offering of Units
-
Roth Capital Upgrades Diamondback Energy (FANG) to Buy
-
Check-Cap Ltd. Announces $5.9 Million Financing
-
Roth Affirms Manitex (MNTX) at 'Buy'; Cost Improvement Initiatives Shine in Q2
-
Streetinsider.com's Hot Lunchtime Reads 8/5: (MU) (MRK) (LGND) (FIVE)
-
Roth Capital Says to Buy Ligand Pharma (LGND) on Today's 'Bad' Downgrade
-
Notable Analyst Rating Changes 8/5: (SYMC) (COH) (OAS) Upgraded; (ICPT) (PKI) (REGN) Downgraded
-
Capstone Turbine (CPST) Moves Past Transitional Year; Pipeline Remains Robust - Roth Capital
-
Roth Capital Downgrades Super Micro Computer (SMCI) to Neutral
-
Roth Capital Downgrades ReneSola Ltd. (SOL) to Sell
-
Roth Capital Resumes Pieris Pharmaceuticals (PIRS) at Buy
-
Roth Capital Downgrades JinkoSolar Holding Co., Ltd. (JKS) to Neutral
-
Canadian Solar (CSIQ) Better-Positioned vs. Peers Amid Expected Solar Glut - Roth Capital
-
Palatin Technologies Announces Closing of $9.2 Million Financing
-
Roth Keeps Regeneron (REGN) at 'Buy' Following Q2 Report; Says 'Blocking and Tackling' Continues
-
Roth Capital Bumps PT on Ligand Pharma (LGND) up to $149; Says Running on All Cylinders
-
Streetinsider.com's Hot Lunchtime Reads 8/4: (P) (QTWO) (JACK) (FSLR)
-
Roth Capital Sees FY17 Ests on First Solar (FSLR) Turning Lower; Trims PT to $55

